| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.984 | 0.001 | 0.984 | Proto-oncogene tyrosine-protein kinase Met inhibitor | 0.952 0.002 DBMET03537 | ||
| 0.944 | 0.004 | 0.944 | Tyrosine kinase inhibitor | 0.925 0.004 DBMET03537 | ||
| 0.783 | 0.003 | 0.783 | Hepatocyte growth factor antagonist | 0.701 0.003 DBMET03537 | ||
| 0.756 | 0.005 | 0.756 | Growth factor antagonist | 0.626 0.006 DBMET03537 | ||
| 0.526 | 0.003 | 0.526 | Activin receptor-like kinase 2 inhibitor | 0.472 0.004 DBMET03537 | ||
| 0.512 | 0.005 | 0.512 | Tyrosine-protein kinase receptor antagonist | 0.474 0.005 DBMET03537 | ||
| 0.508 | 0.004 | 0.508 | Macrophage colony-stimulating factor 1 receptor antagonist | 0.44 0.004 DBMET03537 | ||
| 0.491 | 0.006 | 0.491 | TRKC antagonist | 0.46 0.008 DBMET03537 | ||
| 0.485 | 0.004 | 0.485 | ALK inhibitor | 0.438 0.004 DBMET03537 | ||
| 0.471 | 0.007 | 0.471 | Interleukin-1 receptor-associated protein kinase 1 inhibitor | 0.433 0.009 DBMET03537 | ||
| 0.456 | 0.004 | 0.456 | TRKA antagonist | 0.409 0.005 DBMET03537 | ||
| 0.413 | 0.003 | 0.413 | I kappa B kinase epsilon inhibitor | 0.356 0.004 DBMET03537 | ||
| 0.4 | 0.002 | 0.4 | Toll-Like receptor 3 antagonist | 0.365 0.003 DBMET03537 | ||
| 0.357 | 0.004 | 0.357 | MAP kinase kinase kinase inhibitor | 0.321 0.005 DBMET03537 | ||
| 0.348 | 0.004 | 0.348 | AXL receptor tyrosine kinase inhibitor | 0.274 0.005 DBMET03537 | ||
| 0.334 | 0.008 | 0.334 | TRKB antagonist | 0.294 0.011 DBMET03537 | ||
| 0.315 | 0.004 | 0.315 | MAP3K7 inhibitor | 0.287 0.004 DBMET03537 | ||
| 0.418 | 0.129 | 0.418 | Antiinflammatory | 0.388 0.146 DBMET03537 | ||
| 0.268 | 0.011 | 0.268 | Granulocyte macrophage colony stimulating factor antagonist | 0.207 0.02 DBMET03537 | ||
| 0.266 | 0.011 | 0.266 | Toll-Like receptor antagonist | 0.118 0.088 DBMET03537 | ||
| 0.267 | 0.03 | 0.267 | LIM domain kinase 1 inhibitor | 0.234 0.046 DBMET03537 | ||
| 0.255 | 0.023 | 0.255 | Polo-like kinase-3 inhibitor | 0.236 0.029 DBMET03537 | ||
| 0.255 | 0.035 | 0.29 | Focal adhesion kinase 2 inhibitor | 0.29 0.019 DBMET03537 | DBMET03537 | |
| 0.242 | 0.029 | 0.242 | Vascular endothelial growth factor 3 antagonist | 0.203 0.041 DBMET03537 | ||
| 0.204 | 0.015 | 0.204 | Fibroblast growth factor 1 antagonist | 0.17 0.025 DBMET03537 | ||
| 0.245 | 0.06 | 0.245 | EphB2 antagonist | 0.215 0.078 DBMET03537 | ||
| 0.186 | 0.003 | 0.186 | Toll-Like receptor 8 antagonist | 0.106 0.008 DBMET03537 | ||
| 0.196 | 0.015 | 0.196 | EphA2 antagonist | 0.18 0.019 DBMET03537 | ||
| 0.19 | 0.013 | 0.19 | Janus tyrosine kinase 2 inhibitor | 0.139 0.023 DBMET03537 | ||
| 0.16 | 0.005 | 0.16 | Toll-Like receptor 7 antagonist | 0.113 0.014 DBMET03537 | ||
| 0.173 | 0.02 | 0.173 | Activin receptor-like kinase 4 inhibitor | 0.137 0.036 DBMET03537 | ||
| 0.159 | 0.008 | 0.159 | Janus tyrosine kinase 1 inhibitor | 0.125 0.014 DBMET03537 | ||
| 0.192 | 0.042 | 0.192 | Cyclin-dependent kinase 8 inhibitor | 0.184 0.047 DBMET03537 | ||
| 0.16 | 0.012 | 0.16 | Tyk2 inhibitor | 0.132 0.018 DBMET03537 | ||
| 0.196 | 0.049 | 0.202 | Protein kinase C nu inhibitor | 0.202 0.046 DBMET03537 | DBMET03537 | |
| 0.18 | 0.034 | 0.18 | Protein-tyrosine kinase (PTK, not ETK, WZC) inhibitor | 0.141 0.052 DBMET03537 | ||
| 0.179 | 0.034 | 0.179 | Abl kinase inhibitor | 0.141 0.052 DBMET03537 | ||
| 0.291 | 0.148 | 0.291 | Analgesic | 0.244 0.188 DBMET03537 | ||
| 0.179 | 0.043 | 0.179 | Cyclin-dependent kinase 7 inhibitor | 0.145 0.064 DBMET03537 | ||
| 0.254 | 0.12 | 0.254 | Angiogenesis inhibitor | 0.242 0.129 DBMET03537 | ||
| 0.18 | 0.048 | 0.18 | RET inhibitor | 0.146 0.064 DBMET03537 | ||
| 0.135 | 0.018 | 0.135 | Fibroblast growth factor 3 antagonist | 0.097 0.035 DBMET03537 | ||
| 0.125 | 0.016 | 0.125 | Fibroblast growth factor 2 antagonist | 0.067 0.044 DBMET03537 | ||
| 0.272 | 0.164 | 0.279 | MAP kinase kinase 6 inhibitor | 0.279 0.157 DBMET03537 | DBMET03537 | |
| 0.136 | 0.033 | 0.136 | Protein kinase (Mos, Mil/Raf, MEKK, RIPK, TESK, LIMK, IRAK, ILK, Activin/TGF-beta) inhibitor | 0.105 0.049 DBMET03537 | ||
| 0.114 | 0.013 | 0.114 | Transforming growth factor beta 3 antagonist | 0.101 0.022 DBMET03537 | ||
| 0.134 | 0.034 | 0.134 | Insulin receptor antagonist | 0.116 0.045 DBMET03537 | ||
| 0.124 | 0.024 | 0.124 | Protein kinase B gamma inhibitor | 0.094 0.036 DBMET03537 | ||
| 0.137 | 0.041 | 0.137 | Ephrin antagonist | 0.117 0.052 DBMET03537 | ||
| 0.117 | 0.022 | 0.117 | Purinergic P2X2 antagonist | 0.094 0.033 DBMET03537 | ||
| 0.121 | 0.031 | 0.121 | Leucine-rich repeat kinase 2 inhibitor | 0.109 0.037 DBMET03537 | ||
| 0.106 | 0.026 | 0.106 | Protein kinase B alpha inhibitor | 0.072 0.046 DBMET03537 | ||
| 0.182 | 0.105 | 0.182 | Ca2+/calmodulin-dependent kinase I alpha inhibitor | 0.171 0.117 DBMET03537 | ||
| 0.144 | 0.075 | 0.144 | Hemostatic | 0.12 0.114 DBMET03537 | ||
| 0.103 | 0.043 | 0.103 | Interleukin-1 receptor-associated protein kinase 4 inhibitor | 0.09 0.056 DBMET03537 | ||
| 0.085 | 0.027 | 0.085 | Raf kinase B inhibitor | 0.061 0.04 DBMET03537 | ||
| 0.09 | 0.032 | 0.09 | Protein kinase B beta inhibitor | 0.074 0.05 DBMET03537 | ||
| 0.085 | 0.031 | 0.085 | Transforming growth factor antagonist | 0.069 0.05 DBMET03537 | ||
| 0.092 | 0.037 | 0.092 | Raf kinase inhibitor | 0.071 0.054 DBMET03537 | ||
| 0.093 | 0.048 | 0.093 | Bcr-Abl kinase inhibitor | |||
| 0.11 | 0.067 | 0.137 | Polo-like kinase-4 inhibitor | 0.137 0.044 DBMET03537 | DBMET03537 | |
| 0.07 | 0.027 | 0.07 | Fibroblast growth factor 4 antagonist | 0.056 0.042 DBMET03537 | ||
| 0.086 | 0.045 | 0.086 | Proto-oncogene tyrosine-protein kinase c-hck inhibitor | 0.072 0.065 DBMET03537 | ||
| 0.089 | 0.05 | 0.089 | mTOR complex 2 inhibitor | |||
| 0.084 | 0.049 | 0.084 | ErbB-4 antagonist | |||
| 0.133 | 0.099 | 0.133 | MAP kinase 3 inhibitor | |||
| 0.061 | 0.029 | 0.061 | Phosphatidylinositol 3-kinase alpha inhibitor | |||
| 0.045 | 0.018 | 0.045 | 5 Hydroxytryptamine 2B agonist | |||
| 0.119 | 0.092 | 0.143 | Ribosomal protein S6 kinase inhibitor | 0.143 0.07 DBMET03537 | DBMET03537 | |
| 0.115 | 0.089 | 0.115 | Protein-tyrosine kinase Lyn inhibitor | |||
| 0.064 | 0.038 | 0.064 | Phosphatidylinositol kinase inhibitor | |||
| 0.157 | 0.131 | 0.157 | Potassium channel (Voltage-sensitive) blocker | |||
| 0.153 | 0.128 | 0.153 | HERG channel blocker | |||
| 0.024 | 0.005 | 0.024 | Nicotinic alpha4 receptor agonist | |||
| 0.028 | 0.01 | 0.028 | Phosphodiesterase 9A inhibitor | 0.027 0.013 DBMET03537 | ||
| 0.028 | 0.01 | 0.028 | Phosphodiesterase IX inhibitor | 0.026 0.013 DBMET03537 | ||
| 0.208 | 0.191 | 0.208 | Toll-Like receptor 7 agonist | |||
| 0.051 | 0.036 | 0.051 | Factor IXa inhibitor | |||
| 0.123 | 0.109 | 0.159 | MAP3K9 inhibitor | 0.159 0.047 DBMET03537 | DBMET03537 | |
| 0.097 | 0.086 | 0.097 | Aurora-B kinase inhibitor | |||
| 0.205 | 0.196 | 0.205 | Toll-Like receptor agonist | |||
| 0.092 | 0.082 | 0.092 | mTOR complex 1 inhibitor | |||
| 0.081 | 0.074 | 0.081 | Bromodomain-containing protein 2 inhibitor | |||
| 0.13 | 0.123 | 0.13 | Antipruritic | |||
| 0.041 | 0.036 | 0.041 | 5 Hydroxytryptamine 2C agonist | |||
| 0.075 | 0.07 | 0.103 | MAP-kinase-activated kinase inhibitor | 0.103 0.036 DBMET03537 | DBMET03537 | |
| 0.045 | 0.041 | 0.045 | Bromodomain-containing protein 3 inhibitor | |||
| 0.031 | 0.028 | 0.031 | Transforming growth factor beta 2 antagonist | |||
| 0.065 | 0.067 | 0.091 | MAP-kinase-activated kinase 2 inhibitor | 0.091 0.034 DBMET03537 | DBMET03537 | |
| 0.165 | 0.211 | 0.204 | Immunomodulator | 0.204 0.159 DBMET03537 | DBMET03537 | |
| 0.068 | 0.119 | 0.084 | Polo-like kinase-1 inhibitor | 0.084 0.075 DBMET03537 | DBMET03537 | |
| 0.143 | 0.197 | 0.168 | MAP-kinase-activated kinase 5 inhibitor | 0.168 0.152 DBMET03537 | DBMET03537 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |